-
A Drug That Mimics Alcohol Buzz Is Bound For Human Trials: Here's What's Next
Friday, March 17, 2023 - 11:30am | 326Israeli biotech Clearmind Medicine Inc. (NASDAQ: CMND) has submitted an Investigational New Drug (IND) application with the FDA towards approval to commence its first-in-human Phase 1/2a clinical trial with MEAI-based CMND-100 in patients diagnosed with Alcohol Use Disorder (AUD). The active...
-
Shark Tank's Kevin Harrington Will Provide Strategic Guidance To Major Psychedelics Company
Tuesday, February 28, 2023 - 3:29pm | 541Psychedelics biopharma company FSD Pharma Inc. (NASDAQ: HUGE)’s advisory board has a new member: the iconic entrepreneur and inventor of the infomercial Kevin Harrington. In addition to helping develop its R&D programs as well as product development,...
-
Awakn's First Licensing Partnership Deal In Europe Involves Chain Of Portuguese Clinics
Wednesday, February 22, 2023 - 2:28pm | 316Awakn Life Sciences Corp. (OTCQB: AWKNF) has signed a licensing partnership agreement in Europe with a Portugal-based healthcare consortium currently operating in stealth mode. This is the first time Awakn, a psychedelics biotech and services provider, will license its protocols...
-
Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program
Tuesday, February 14, 2023 - 3:25pm | 623Awakn Opens Fourth European Clinic, Norway Takes Center Stage Awakn Life Sciences Corp. (OTCQB: AWKNF), a psychedelics biotech company with a near-term focus on Alcohol Use Disorder (AUD), has opened a new clinic providing its proprietary ketamine-assisted psychotherapy (KAP) in the center of...
-
Clinical Site In Alberta Begins Study Of Psychedelic-Assisted Treatment For Alcohol Use Disorder
Tuesday, February 7, 2023 - 6:37pm | 296Calgary-based SABI Mind is the first clinical site to receive approval from the Health Research Ethics Board of Alberta (HREBA) to launch a trial assessing psilocybin-assisted psychotherapy for the treatment of Alcohol Use Disorder (AUD). Sponsored by Canadian biotech company Clairvoyant...
-
Awakn's Ketamine Treatment For Alcohol Use Disorder Awarded UK's Fast-Track Status
Tuesday, February 7, 2023 - 12:10pm | 339Awakn Life Sciences Corp. (OTCQB: AWKNF), a biotech company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), has been granted an Innovation Passport for its proprietary Ketamine-Assisted Therapy (KAT) to treat severe AUD. The passport...
-
Recreational Cannabis Legalization Correlated With Decrease In Alcohol Use Disorder, New Study Finds
Monday, January 30, 2023 - 6:56pm | 585A new study published in Psychological Medicine shows evidence that legalizing cannabis does not increase substance use disorders or use of other illicit drugs and therefore is not considered a gateway drug. In fact, cannabis may actually reduce alcohol-related problems said researchers...
-
EXCLUSIVE: Next-Generation Psychedelics, MEAI - What And When
Tuesday, January 24, 2023 - 4:32pm | 573(Part three of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains MEAI is a potent synthetic molecule essentially developed in the...
-
Psychiatry And Business Collaborate: European Psychedelics Trial Tackles Alcohol Addiction
Friday, January 20, 2023 - 7:37pm | 313Clinical-stage natural psychedelics developer Filament Health (OTCQB: FLHLF) and the Psychiatric Center Copenhagen’s collaborative clinical trial has been approved by the Danish Medicines Agency and is set to commence this February. The study, to be led by Prof. Anders Fink-...
-
These Are The 11 Biggest Psychedelics News And Trends You May Have Missed Last Year
Wednesday, January 4, 2023 - 12:48pm | 4975What a year for psychedelics! It feels like we’ve come a long way since the sector explode in 2019-2020, the launch of Benzinga's Psyched, companies’ massive migration from private to public, MAPS’ initiation of Phase 3 MDMA trials, the surge of the psilocybin wave,...
-
Europe To Have Expanded Access To Psychedelic-Assisted Therapy With New Norway Clinic
Saturday, December 3, 2022 - 3:00pm | 364Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) announced the continuation of its Nordic expansion plans with a new 5-year lease for the opening of a clinic in the center of Trondheim. Awakn’s CEO Anthony Tennyson stated this is a “real momentum growing” for the...
-
Clearmind Gears Up For Clinical Trial To Test Drug That Treats Alcohol Addiction
Wednesday, November 23, 2022 - 4:22pm | 455Israeli psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) is commencing the production of its proprietary drug candidate based on the MEAI molecule. It will be used in the upcoming Phase 1 clinical trial assessing the treatment of Alcohol Use Disorder (AUD). "Like other addictions,...
-
A Leading Ketamine Treatment Clinic For Alcoholism Is Expanding: Here's The Latest
Wednesday, November 23, 2022 - 2:27pm | 453A psychedelics R&D biotech company, known for providing novel treatments for addictions, is opening a new ketamine clinic. Awakn Life Sciences Corp. (OTCQB: AWKNF) just signed a five-year lease in Oslo as part of the company’s Nordic expansion plans. Awakn’s new Norwegian...
-
EXCLUSIVE: New Partnership Brings Leading Psychedelic Protocol For Alcoholism Treatment To NYC
Wednesday, November 9, 2022 - 8:00am | 820NYC-based clinics brand Nushama has partnered with Awakn Life Sciences (OTCQB: AWKNF), a clinical-stage psychedelics biotech company to bring Awakn’s advanced ketamine-assisted therapy treatment for AUD to Nushama’s New York clinics. They intend to provide sustained...
-
Can Ketamine Treat Alcohol Addiction? In-Clinic Therapy Vs. Retreats
Thursday, October 13, 2022 - 11:25am | 952(Part four of a four-part series - Read part three) The reason why companies offering psychedelic-assisted therapy only use ketamine is that at the moment it is the only one that holds a medical license. While psilocybin and MDMA are showing enormous promise, they are still in ...